rajasekharkakarla
☆    

India,
2018-07-24 09:05
(1228 d 08:51 ago)

Posting: # 19087
Views: 2,178
 

 Reference trademark issue [Regulatives / Guidelines]

Dear All,

I prepared protocol for Mesalamine delayed-release tablets 1.2 gm for USFDA submission, i written reference name as Lialda™ (mesalamine) delayed release tablets 1.2 gm with trademark TM and the protocol was approved by EC. But as per COA it is mentioned as Lialda®, there is change in trademark. kindly suggest whether i need to go with ammendment/not.

Regards'
Kakarla
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2018-07-24 16:57
(1228 d 00:59 ago)

@ rajasekharkakarla
Posting: # 19093
Views: 2,044
 

 Note to File

Hi Kakarla,

IMHO, no big deal.
stands for an unregistered trademark, as opposed to an registered trademark ®. Will not affect the safety of the subjects in the study. Hence, no substantial amendment (EC and regulatory approval) is required. Maybe just a “Note to File” is enough. If you want to be on the safe side, go for an administrative amendment.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
rajasekharkakarla
☆    

India,
2018-07-30 13:37
(1222 d 04:19 ago)

@ Helmut
Posting: # 19115
Views: 2,167
 

 Note to File

Dear Sir,

Thank you for your clarification.

Thanks and Regards,
Kakarla Rajasekhar
Activity
 Admin contact
21,785 posts in 4,556 threads, 1,547 registered users;
online 6 (0 registered, 6 guests [including 5 identified bots]).
Forum time: Friday 16:56 CET (Europe/Vienna)

A drug is that substance which, when injected into a rat,
will produce a scientific report.    Anonymous

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5